Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.

Journal article

González-Martínez I. et al, (2023), Mol Ther Nucleic Acids, 34

EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method

Journal article

Hanson B. et al, (2023), Molecular Therapy - Nucleic Acids, 33, 511 - 528

Therapeutic approaches for Duchenne muscular dystrophy.

Journal article

Roberts TC. et al, (2023), Nat Rev Drug Discov

Oral delivery of layer-by-layer coated exosomes for colitis therapy.

Journal article

Deng C. et al, (2023), J Control Release, 354, 635 - 650

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.

Journal article

Stoodley J. et al, (2023), Int J Mol Sci, 24

Biodistribution of therapeutic extracellular vesicles

Journal article

Gupta D. et al, (2023), Extracellular Vesicles and Circulating Nucleic Acids, 4, 170 - 190

Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.

Journal article

Stoodley J. et al, (2023), Methods Mol Biol, 2587, 209 - 237

RNase-H-mediated silencing in the CNS proves predictably nontrivial.

Journal article

Moazami MP. and Wood MJA., (2022), Med (N Y), 3, 733 - 734

Load More